(Total Views: 617)
Posted On: 09/17/2024 3:54:02 PM
Post# of 154725
Data from the first interim analysis of the Phase 3 known as LEAP-012 show median progression-free survival of 14.6 mos. for the patients on the combination... versus 10 mos. for those in the placebo group.
Butt,...the coupling which experienced 3 late-stage failures last year... still needs to hit an over-all survival and prove that SIDE effects are worth the RISK...before Merck and ESAI seek regulatory approval.
It's a race between efficacy and Toxicity. On the toxicity side about 71% of patients on the combo regimen experienced grade 3-4 treatment related adverse events or Died...versus 31.5% in the placebo group.
About 8.4% of patients on the blockbuster drugs...discontinued because of treatment issues...whereas only 1.2% of the placebo group could say the same.
Merck said the 5 year OS rate was in favor of KEYTRUDA ...and is statistically significant @ 86.6% versus 81.7% ...with Chemo alone.
There is about a half dozen players in this space. It will be interesting to see how...and where We stand...on the subject indication.
Butt,...the coupling which experienced 3 late-stage failures last year... still needs to hit an over-all survival and prove that SIDE effects are worth the RISK...before Merck and ESAI seek regulatory approval.
It's a race between efficacy and Toxicity. On the toxicity side about 71% of patients on the combo regimen experienced grade 3-4 treatment related adverse events or Died...versus 31.5% in the placebo group.
About 8.4% of patients on the blockbuster drugs...discontinued because of treatment issues...whereas only 1.2% of the placebo group could say the same.
Merck said the 5 year OS rate was in favor of KEYTRUDA ...and is statistically significant @ 86.6% versus 81.7% ...with Chemo alone.
There is about a half dozen players in this space. It will be interesting to see how...and where We stand...on the subject indication.
(5)
(0)
